Skip to main content

Table 3 Treatment response and oncological outcome

From: Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)

Patient

Tumor site, histology and size

Sunitinib dose

RT dose

Resection margin

RECIST

% non-viable tissue

Follow-up status (and time), events (months after ED)

1

lower extremity, myxofibrosarcoma, 11 cm

25

50.4

R0

stable disease

30 %

NED (29mo), LR resected (19 mo)

2

lower extremity, dediff. lipo, 8 cm

25

50.4

R0

stable disease

95 %

AWD (36 mo), Soft tissue mets (15 mo)

3

Retroperitoneal, dediff. lipo, 15 cm

25

50.4

R1

stable disease

75 %

NED (28 mo)

4

Retroperitoneal, dediff. lipo, 12 cm

25

50.4

R1

stable disease

20 %

NED (11 mo)

5

Retroperitoneal, undiff. pleomorphic sarcoma, 14 cm

25

50.4

R2 (primary Tumor R0)

progressive disease (locally and mets)

70 %

DOD (9 mo), Liver mets at surgery

6

Groin, Dediff. lipo, 20 cm

25

50.4

R0

stable disease

30 %

NED (24 mo)

7

Retroperitoneal, myxoidlipo, 5 cm

37.5

50.4

R0

partial response

50 %

NED (20 mo)

8

lower extremity, synovial sarcoma, 8 cm

37.5

50.4

R0

stabledisease

100 %

AWD (23 mo), Lung mets (15 mo)

9

chest wall, undiff. pleomorphic sarcoma, 5 cm

37.5

50.4

R0

stabledisease

100 %

NED (13 mo)